We are live on ! Find out more

Artivion

AORT

Market cap $1.31B

26.77 USD

+0.10

0.37%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

26.77

0.00

0%

1 day

0.37%

5 days

-4.43%

1 month

-0.89%

3 months

18.61%

6 months

-30.56%

Year to date

-39.79%

1 year

-38.9%

5 years

3.96%

10 years

63.33%

About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Employees: 1,800

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 63.6%

Negative 0%

Artivion Q2 Earnings Call Highlights

Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.

Artivion Q2 Earnings Call Highlights

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion Reports Second Quarter 2026 Financial Results

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.

Artivion Reports Second Quarter 2026 Financial Results

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. We remain encouraged by PLMR's disciplined underwriting approach, diversified specialty portfolio, and ability to historically deploy capital into attractive growth opportunities.

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells

Artivion to Participate in Upcoming Investor Conferences

ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at the InterContinental Boston Hotel.

Artivion to Participate in Upcoming Investor Conferences

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

Zacks Investment Research

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.

Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion

Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major adverse events, with the elimination of DANE tears and durable benefit, supporting rapid, adoption-driven commercial scaling. AORT demonstrates double-digit revenue growth, margin expansion, and a shift to GAAP profitability, with EBITDA up 26% and gross margins nearing 65%.

Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections.

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

See News Rankings

Price charts implemented using Lightweight Charts™